Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD.

Cancer Med. 2020 Mar 18. doi: 10.1002/cam4.2998. [Epub ahead of print]

2.

Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement.

Deshpande S, Gertz MA, Dispenzieri A, Kumar SS, Parikh SA, Muchtar E.

Leuk Lymphoma. 2020 Mar 11:1-4. doi: 10.1080/10428194.2020.1737688. [Epub ahead of print] No abstract available.

PMID:
32159403
3.

The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis.

Muchtar E, Lin G, Grogan M.

Can J Cardiol. 2020 Mar;36(3):384-395. doi: 10.1016/j.cjca.2019.11.032. Epub 2019 Dec 9. Review.

PMID:
32145866
4.

Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.

Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go R, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK, Gonsalves WI.

Am J Hematol. 2020 Mar 4. doi: 10.1002/ajh.25773. [Epub ahead of print]

PMID:
32129510
5.

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.

Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Fonder A, Hobbs M, Jevremovic D, Lust JA, Zeldenrust S, Russell SJ, Rajkumar SV, Gertz MA, Murray D.

Blood Cancer J. 2020 Feb 25;10(2):20. doi: 10.1038/s41408-020-0291-8.

6.

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Gertz MA, Kumar SK.

Am J Hematol. 2020 Feb 3. doi: 10.1002/ajh.25746. [Epub ahead of print]

PMID:
32010993
7.

Utility of serum free light chain ratio in response definition in patients with multiple myeloma.

Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2020 Jan 28;4(2):322-326. doi: 10.1182/bloodadvances.2019001099. No abstract available.

8.

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA.

Haematologica. 2020 Jan 23. pii: haematol.2019.240564. doi: 10.3324/haematol.2019.240564. [Epub ahead of print] No abstract available.

9.

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.

Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A.

Blood Cancer J. 2020 Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9.

10.

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.

Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2020 Mar;95(3):310-315. doi: 10.1002/ajh.25709. Epub 2020 Jan 8.

PMID:
31867775
11.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.

Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P.

Am J Hematol. 2020 Mar;95(3):274-281. doi: 10.1002/ajh.25697. Epub 2019 Dec 31.

PMID:
31814157
12.

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA.

Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. No abstract available.

PMID:
31788844
13.

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.

Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves WI, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, Lacy MQ, Buadi FK, Leung N, Kyle RA, Kumar SK, King RL, Gertz MA.

Leukemia. 2019 Nov 28. doi: 10.1038/s41375-019-0667-6. [Epub ahead of print]

PMID:
31780812
14.

Revisiting complete response in light chain amyloidosis.

Sidana S, Dispenzieri A, Murray DL, Go RS, Buadi FK, Lacy MQ, Gonsalves WI, Dingli D, Warsame R, Kourelis T, Muchtar E, Hayman SR, Kapoor P, Kyle RA, Leung N, Rajkumar SV, Gertz MA, Kumar SK.

Leukemia. 2019 Nov 26. doi: 10.1038/s41375-019-0664-9. [Epub ahead of print] No abstract available.

PMID:
31772296
15.

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A.

Leukemia. 2020 Apr;34(4):1135-1143. doi: 10.1038/s41375-019-0655-x. Epub 2019 Nov 22.

PMID:
31758090
16.

New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Vaxman I, Dispenzieri A, Muchtar E, Gertz M.

Blood Rev. 2020 Mar;40:100636. doi: 10.1016/j.blre.2019.100636. Epub 2019 Nov 2. Review.

PMID:
31706583
17.

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.

Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):53-56. doi: 10.1016/j.clml.2019.09.624. Epub 2019 Oct 9.

PMID:
31685378
18.

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.

Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2020 Jan;95(1):4-9. doi: 10.1002/ajh.25657. Epub 2019 Oct 29.

PMID:
31612526
19.

Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.

Al Saleh AS, Sidiqi MH, Gertz MA, Muchtar E, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Buadi FK, Dispenzieri A, Dingli D, Kumar SK.

Am J Hematol. 2020 Jan;95(1):E8-E10. doi: 10.1002/ajh.25654. Epub 2019 Oct 21. No abstract available.

PMID:
31591735
20.

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23.

PMID:
31544536
21.

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.

Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P.

Br J Haematol. 2020 Feb;188(3):394-403. doi: 10.1111/bjh.16168. Epub 2019 Aug 29.

PMID:
31468508
22.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486. No abstract available.

PMID:
31343331
23.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Dec;187(5):588-594. doi: 10.1111/bjh.16096. Epub 2019 Jul 12.

PMID:
31298751
24.

Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis.

Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Wolf RC, Kapoor P, Buadi FK, Kumar SK, Gertz MA.

Am J Hematol. 2019 Oct;94(10):1066-1071. doi: 10.1002/ajh.25572. Epub 2019 Jul 23.

PMID:
31273808
25.

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.

Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA.

Am J Hematol. 2019 Sep;94(9):1020-1026. doi: 10.1002/ajh.25566. Epub 2019 Jul 11.

PMID:
31254301
26.

Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.

27.

The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2019 Dec;54(12):2039-2050. doi: 10.1038/s41409-019-0590-5. Epub 2019 Jun 12.

28.

Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1520-1525. doi: 10.1016/j.bbmt.2019.04.024. Epub 2019 May 2.

PMID:
31054986
29.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.

PMID:
31014142
30.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

31.

The colorful landscape of multiple myeloma.

Muchtar E, Gertz MA.

Leuk Lymphoma. 2019 Sep;60(9):2099-2100. doi: 10.1080/10428194.2019.1585842. Epub 2019 Feb 27. No abstract available.

PMID:
30810426
32.

Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis.

Sidiqi MH, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Grogan M, Lust JA, Kumar S, Kyle RA, Rajkumar VS, Gertz M, Dispenzieri A.

Am J Hematol. 2019 May;94(5):E141-E143. doi: 10.1002/ajh.25440. Epub 2019 Feb 27. No abstract available.

PMID:
30773682
33.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13. Erratum in: Mayo Clin Proc. 2019 Jun;94(6):1121.

PMID:
30770096
34.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8.

PMID:
30737485
35.

Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis.

Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, Kumar SK, Kourelis TV.

Mayo Clin Proc. 2019 Mar;94(3):455-464. doi: 10.1016/j.mayocp.2018.08.039. Epub 2019 Feb 2.

PMID:
30718070
36.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
37.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

38.

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Muchtar E, Kumar SK, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, Dispenzieri A.

Blood. 2019 Feb 14;133(7):763-766. doi: 10.1182/blood-2018-10-875252. Epub 2018 Dec 13. No abstract available.

PMID:
30545829
39.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

40.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

41.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2019 Jul;54(7):1077-1081. doi: 10.1038/s41409-018-0388-x. Epub 2018 Nov 2.

PMID:
30390060
42.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315235
43.

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.

Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, Kumar S, Kapoor P.

Leukemia. 2019 Feb;33(2):531-536. doi: 10.1038/s41375-018-0262-2. Epub 2018 Sep 28. No abstract available.

PMID:
30267007
44.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. No abstract available.

PMID:
30258095
45.

Safety of Sedation for Patients Undergoing Bone Marrow Biopsy and Aspiration While Febrile.

Warner ME, Martin DP, Muchtar E, Sprung J, Weingarten TN, Warner MA.

Mayo Clin Proc Innov Qual Outcomes. 2017 Dec 11;2(1):26-29. doi: 10.1016/j.mayocpiqo.2017.11.003. eCollection 2018 Mar.

46.

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.

Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Dec;93(12):1518-1523. doi: 10.1002/ajh.25279. Epub 2018 Oct 2.

47.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P.

Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2.

48.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.

49.

Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response.

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Muchtar E, Lust JA, Rajkumar VS, Gertz MA.

Bone Marrow Transplant. 2019 Mar;54(3):442-447. doi: 10.1038/s41409-018-0280-8. Epub 2018 Aug 7.

PMID:
30087461
50.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9. Review.

Supplemental Content

Loading ...
Support Center